We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
That being said, low-priced stocks can be attractive to smaller investors that can’t necessarily afford large stakes in companies with higher priced stocks. When looking at these low-priced stocks, we can look at the same trends in growth, value, and momentum and apply the Zacks Rank to properly analyze the potential that these companies have.
Today we’ve highlighted three stocks that fall into broad “medical” sector. Each of these three stocks is currently trading for less than $10 per share and holds a Zacks Rank #2 (Buy) or higher. Take a look at the strong estimate revision activity and other factors that make these companies stick out right now:
1. Heat Biologics
Previous Close: $1.35
Heat Biologics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of cellular therapeutic vaccines for cancers and infectious diseases. While the company remains loss-making, its current-quarter Zacks Consensus Estimate has gained seven cents in the past 30 days after two positive estimate revisions over that time. Heat Biologics has also seen positive estimate revisions for its next-quarter and full-year earnings; this activity has earned the stock a Zacks Rank #2 (Buy).
2. Intec Pharma
Previous Close: $6.07
Intec Pharma is a biopharmaceutical company that develops drugs through its proprietary Accordion Pill technology platform; it currently has treatments for Parkinson’s and insomnia in development. The company’s current-quarter Zacks Consensus Estimate has gained seven cents over the last 30 days, and the stock has been on a solid run recently. Shares have gained 48% in the past 12 weeks, giving the company an “A” grade for Momentum along with its Zacks Rank #2 (Buy).
Lantheus Holdings is a producer of diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. The company has seen strong estimate revision activity recently, including two positive revisions for its current-quarter earnings, three for its next-quarter earnings, and three for its next-year earnings. Lantheus also has a history of outperforming estimates; the company has surpassed the Zacks Consensus Estimate by an average of 267% in each of the trailing four quarters. It also has “A” grades for Value and Momentum to go along with its Zacks Rank #1 (Strong Buy).
Bottom Line
A stock’s market price is not a clear indicator of whether it is a good investment. However, the nice thing about the Zacks Rank is that it can be applied to stocks of any price. All of the stocks highlighted today have a strong Zacks Rank, and their respective industries within the medical sector rank highly in the Zacks Industry Rank. Throw in the other positive qualities we’ve highlighted today and it looks like these could be great under $10 picks right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Medical Stocks Under $10 to Buy Now
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
That being said, low-priced stocks can be attractive to smaller investors that can’t necessarily afford large stakes in companies with higher priced stocks. When looking at these low-priced stocks, we can look at the same trends in growth, value, and momentum and apply the Zacks Rank to properly analyze the potential that these companies have.
Today we’ve highlighted three stocks that fall into broad “medical” sector. Each of these three stocks is currently trading for less than $10 per share and holds a Zacks Rank #2 (Buy) or higher. Take a look at the strong estimate revision activity and other factors that make these companies stick out right now:
1. Heat Biologics
Previous Close: $1.35
Heat Biologics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of cellular therapeutic vaccines for cancers and infectious diseases. While the company remains loss-making, its current-quarter Zacks Consensus Estimate has gained seven cents in the past 30 days after two positive estimate revisions over that time. Heat Biologics has also seen positive estimate revisions for its next-quarter and full-year earnings; this activity has earned the stock a Zacks Rank #2 (Buy).
2. Intec Pharma
Previous Close: $6.07
Intec Pharma is a biopharmaceutical company that develops drugs through its proprietary Accordion Pill technology platform; it currently has treatments for Parkinson’s and insomnia in development. The company’s current-quarter Zacks Consensus Estimate has gained seven cents over the last 30 days, and the stock has been on a solid run recently. Shares have gained 48% in the past 12 weeks, giving the company an “A” grade for Momentum along with its Zacks Rank #2 (Buy).
3. Lantheus Holdings (LNTH - Free Report)
Previous Close: $7.94
Lantheus Holdings is a producer of diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. The company has seen strong estimate revision activity recently, including two positive revisions for its current-quarter earnings, three for its next-quarter earnings, and three for its next-year earnings. Lantheus also has a history of outperforming estimates; the company has surpassed the Zacks Consensus Estimate by an average of 267% in each of the trailing four quarters. It also has “A” grades for Value and Momentum to go along with its Zacks Rank #1 (Strong Buy).
Bottom Line
A stock’s market price is not a clear indicator of whether it is a good investment. However, the nice thing about the Zacks Rank is that it can be applied to stocks of any price. All of the stocks highlighted today have a strong Zacks Rank, and their respective industries within the medical sector rank highly in the Zacks Industry Rank. Throw in the other positive qualities we’ve highlighted today and it looks like these could be great under $10 picks right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>